Skip to main content

Table 2 Efficacy analysis

From: A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Efficacy response Number of patients
(N = 36)
Complete response 0 (0%)
Partial response 2 (5.6%)
Stable disease 14 (38.9%)
Progressive disease 20 (55.6%)
4-Month clinical benefit rate (4-CBR) 10 (27.8%)
6-Month clinical benefit rate (6-CBR) 6 (16.7%)